

In the specification:

Please amend the portion of the specification beginning at page 19, line 5, and continuing to the first line of page 21 as follows:

(*E,E*)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (CR1);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR2);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile  
(CR3);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
(*E,E*)-2-(phenylethylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5);  
(*E,E*)-2-(phenylethylaminocarbonyl)-3-(3,5-dimethoxy-4-  
hydroxystyryl)acrylonitrile (CR8);  
(*E,E*)-2-(phenylpropylaminocarbonyl)-3-(3,5-dimethoxy-4-  
hydroxystyryl)acrylonitrile (CR9);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-  
hydroxystyryl)acrylonitrile (CR11);  
(*E,E*)-2-aminothiocarbonyl-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12);  
(*E,E*)-2-aminocarbonyl-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13);  
(*E,E*)-2-carboxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR14);  
(*E,E*)-2-carbomethoxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR15);  
(*E,E*)-2-aminocarbonyl-3-[3,4-bis(*t*-  
butyldimethylsilyloxy)styryl]acrylonitrile(CR16);  
(*E,E*)-2-aminocarbonyl-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);  
(*E,E*)-2-(benzylaminocarbonyl)-3-[3,4-bis(*t*-  
butyldimethylsilyloxy)styryl]acrylonitrile (CR18);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile (CR19);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-[3,4-bis(*t*-  
butyldimethylsilyloxy)styryl]acrylonitrile (CR20);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile  
(CR21);  
(*E,E*)-2-( $\beta$ -ethanolaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile  
(CR24);

(*E,E*)-2-(benzylaminocarbonyl)-3-(4-nitrostyryl)acrylonitrile (CR27);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(4-nitrostyryl)acrylonitrile (CR28);  
and  
(*Z,E*)-2-(1-amino-2,2-dicyanoethenyl)-3-(4-nitrostyryl)acrylonitrile (CR29).

In preferred embodiments of the present invention, the compounds of the invention include:

(*E,E*)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (CR1);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR2);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR3);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
(*E,E*)-2-(phenylethylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5);  
(*E,E*)-2-(phenylpropylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR9);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);  
(*E,E*)-2-aminothiocarbonyl-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12);  
(*E,E*)-2-aminocarbonyl-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13);  
(*E,E*)-2-carboxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR14);  
(*E,E*)-2-carbomethoxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR15);  
(*E,E*)-2-aminocarbonyl-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile (CR19);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21); and  
(*E,E*)-2-(β-ethanolaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR24).

In more preferred embodiments of the present invention, the compounds of the invention include:

(*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);

(*E,E*)-2-aminocarbonyl-3-(3,4-dihydroxystyryl)acrylonitril (CR17);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitril (CR19);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile  
(CR21); and  
(*E,E*)-2-( $\beta$ -ethanolaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile

Please amend the section of the specification from page 26, line 8, to page 27, line 16, as follows:

(*E,E*)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (CR1);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR2);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile  
(CR3);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
(*E,E*)-2-(phenylethylaminocarbonyl)-3-(3,4-dimethoxystyryl)acrylonitrile (CR5);  
(*E,E*)-2-(phenylethylaminocarbonyl)-3-(3,5-dimethoxy-4-  
hydroxystyryl)acrylonitrile (CR8);  
(*E,E*)-2-(phenylpropylaminocarbonyl)-3-(3,5-dimethoxy-4-  
hydroxystyryl)acrylonitrile (CR9);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-  
hydroxystyryl)acrylonitrile (CR11);  
(*E,E*)-2-aminothiocarbonyl-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR12);  
(*E,E*)-2-aminocarbonyl-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR13);  
(*E,E*)-2-carboxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR14);  
(*E,E*)-2-carbomethoxy-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR15);  
(*E,E*)-2-aminocarbonyl-3-[3,4-bis(*t*-  
butyldimethylsilyloxy)styryl]acrylonitrile(CR16);  
(*E,E*)-2-aminocarbonyl-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);  
(*E,E*)-2-(benzylaminocarbonyl)-3-[3,4-bis(*t*-  
butyldimethylsilyloxy)styryl]acrylonitrile (CR18);

(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile (CR19);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-[3,4-bis(*t*-butyldimethylsilyloxy)styryl]acrylonitrile (CR20);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21);  
(*E,E*)-2-( $\beta$ -ethanolaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR24);  
(*E,E*)-2-(benzylaminocarbonyl)-3-(4-nitrostyryl)acrylonitrile (CR27);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(4-nitrostyryl)acrylonitrile(CR28);  
and  
(*Z,E*)-2-(1-amino-2,2-dicyanoethenyl)-3-(4-nitrostyryl)acrylonitrile (CR29).

In a preferred embodiment, the present invention provides a method of inhibiting the proliferation of a cancer cell comprising administering an effective amount of a compound selected from the group of compounds:

(*E,E*)-2-(benzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR4);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile (CR11);  
(*E,E*)-2-aminocarbonyl-3-(3,4-dihydroxystyryl)acrylonitrile (CR17);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-styrylacrylonitrile (CR19);  
(*E,E*)-2-(3,4-dihydroxybenzylaminocarbonyl)-3-(3,4-dihydroxystyryl)acrylonitrile (CR21); and  
(*E,E*)-2-( $\beta$ -ethanolaminocarbonyl)-3-(3,5-dimethoxy-4-hydroxystyryl)acrylonitrile